Analysts have been eager to weigh in on the Healthcare sector with new ratings on Mylan Inc (NASDAQ:MYL), Depomed (NASDAQ:DEPO) and ObsEva SA (NASDAQ:OBSV).
Mylan Inc (MYL)
BMO Capital analyst Gary Nachman reiterated a Buy rating on Mylan Inc yesterday and set a price target of $47. The company’s shares closed yesterday at $39.23.
According to TipRanks.com, Nachman is a 4-star analyst with an average return of 11.4% and a 55.6% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Sienna Biopharmaceuticals Inc, Bausch Health Companies Inc, and Pacira Pharmaceuticals.
Mylan Inc has an analyst consensus of Moderate Buy, with a price target consensus of $46.33, implying a 18.1% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $54 price target.
.
See today’s analyst top recommended stocks >>
Depomed (DEPO)
In a report released yesterday, Randall Stanicky from RBC Capital reiterated a Hold rating on Depomed, with a price target of $8. The company’s shares closed yesterday at $7.77.
According to TipRanks.com, Stanicky ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -11.0% and a 32.9% success rate. Stanicky covers the Healthcare sector, focusing on stocks such as Eagle Pharmaceuticals Inc, Pacira Pharmaceuticals, and Evofem Biosciences Inc.
Currently, the analyst consensus on Depomed is a Moderate Buy with an average price target of $8.50.
ObsEva SA (OBSV)
BMO Capital analyst Do Kim reiterated a Buy rating on ObsEva SA yesterday and set a price target of $30. The company’s shares closed yesterday at $14.70.
According to TipRanks.com, Kim is a 4-star analyst with an average return of 19.5% and a 54.3% success rate. Kim covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Akcea Therapeutics Inc, and Alnylam Pharma.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ObsEva SA with a $33.60 average price target, representing a 128.6% upside. In a report issued on July 25, H.C. Wainwright also reiterated a Buy rating on the stock with a $30 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
